Equipotent doses to switch from high doses of opioids to transdermal buprenorphine.

Risultato della ricerca: Articlepeer review

34 Citazioni (Scopus)

Abstract

INTRODUCTION: The aim of this study was to evaluate the equianalgesic ratio of transdermal buprenorphine (TD BUP) with oral morphine and TD fentanyl in a sample of consecutive cancer patients receiving stable doses of 120-240 mg of oral morphine or 50-100 microg of TD fentanyl, reporting adequate pain and symptom control. MATERIALS, METHODS, ANDRESULTS: Patients receiving daily stable doses of opioids for more than 6 days, with no more than two doses of oral morphine (20 and 40 mg, respectively) as needed, were switched to TD BUP using a fentanyl-BUP ratio of 0.6:0.8 and an oral morphine-BUP ratio of 70:1. Opioid doses, pain and symptom intensity, global satisfaction, and number of breakthrough medication were recorded before switching (T0), 3 days after (T3), and 6 days after (T6). Eleven patients were recruited in a period of 1 year, and data were complete for ten patients. The mean age was 61.6 (SD 9.5), and five patients were males. No significant changes in pain and symptom intensity were found, except improvement in reported constipation (p = 0.014), as well as in global satisfaction with the analgesic treatment. No significant changes in breakthrough pain medication were observed.CONCLUSION: The results of this study suggest that stable patients receiving relatively high doses of oral morphine or TD fentanyl could be safely switched to TD BUP, by using a ratio of 70:1 and 0.6:0.8, respectively, maintaining the same level of analgesia.
Lingua originaleEnglish
pagine (da-a)715-718
Numero di pagine4
RivistaSupportive Care in Cancer
Volume17
Stato di pubblicazionePublished - 2009

All Science Journal Classification (ASJC) codes

  • Oncology

Fingerprint Entra nei temi di ricerca di 'Equipotent doses to switch from high doses of opioids to transdermal buprenorphine.'. Insieme formano una fingerprint unica.

Cita questo